Nodular lymphocyte-predominant Hodgkin lymphoma

被引：3

作者：

Fuchs M. ^{[1
]}

Eichenauer D.A. ^{[1
]}

Nogová L. ^{[1
]}

Diehl V. ^{[1
]}

Engert A. ^{[1
]}

机构：

[1] First Department of Internal Medicine, University Hospital of Cologne, 50924 Cologne

来源：

Current Hematologic Malignancy Reports | 2008年 / 3卷 / 3期

关键词：

Hodgkin Lymphoma; Nodular Lymphocyte Predominant Hodgkin Lymphoma; Mediastinal Involvement; German Hodgkin Study Group; British National Lymphoma Investigation;

D O I：

10.1007/s11899-008-0019-5

中图分类号：

学科分类号：

摘要：

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma that differs from classic Hodgkin lymphoma (cHL) with respect to histologic and clinical presentation. Because the prognosis of NLPHL in early unfavorable and advanced stages is similar to that of cHL, treatment is similar. In contrast, early favorable-stage NLPHL has a better prognosis than cHL. Thus, NLPHL in early favorable stages might be treated with reduced-intensity programs without compromising cure rates. Because involved-field radiotherapy alone seems to be as effective as extended-field radiotherapy or combined modalities, it has been adopted by the German Hodgkin Study Group and the European Organisation for Research and Treatment of Cancer as the treatment of choice for stage IA NLPHL. Now that efficacy of the monoclonal antibody rituximab has been shown in relapsed NLPHL, its use in the first-line treatment of NLPHL is under investigation. Copyright © 2008 by Current Medicine Group LLC.

引用

页码：126 / 131

页数：5

共 30 条

[21]

Wirth A., Yuen K., Barton M., Et al., Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: A retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group, Cancer, 104, pp. 1221-1229, (2005)

[22]

Chera B.S., Olivier K., Morris C.G., Et al., Clinical presentation and outcomes of lymphocyte-predominant Hodgkin disease at the University of Florida, Am J Clin Oncol, 30, pp. 601-606, (2007)

[23]

Schlembach P.J., Wilder R.B., Jones D., Et al., Radiotherapy alone for lymphocyte-predominant Hodgkin's disease, Cancer J, 8, pp. 377-383, (2002)

[24]

Raemaekers J., Kluin-Nelemans H., Teodorovic I., Et al., The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer, Eur J Cancer, 38, SUPPL. 4, (2002)

[25]

Savage K.J., Hoskins P., Klasa R., Et al., ABVD chemotherapy is essential for optimal treatment of limited stage nodular lymphocyte predominant Hodgkin Lymphoma, Haematologica, 92, SUPPL. 5, (2007)

[26]

Schulz H., Rehwald U., Morschhauser F., Et al., Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: Long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG), Blood, 111, pp. 109-111, (2008)

[27]

Rehwald U., Schulz H., Reiser M., Et al., Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: Results of a phase 2 trial of the German Hodgkin Lymphoma Study Group, Blood, 101, pp. 420-424, (2003)

[28]

Shimabukuro-Vornhagen A., Haverkamp H., Engert A., Et al., Lymphocyte-rich classical Hodgkin's lymphoma: Clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials, J Clin Oncol, 23, pp. 5739-5745, (2005)

[29]

Feugier P., Labouyrie E., Djeridane M., Et al., Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation, Blood, 104, pp. 2675-2681, (2004)

[30]

Fanale M.A., Fayad L.E., Romaguera J.E., Et al., Experience with R-CHOP in patients with lymphocyte predominant Hodgkin Lymphoma (LPHL), Haematologica, 92, SUPPL. 5, (2007)

← 1 2 3 →